Previous 10 | Next 10 |
ENGLEWOOD, CO / ACCESSWIRE / June 11, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, is set to join the Russell Microcap ® Index at the conclusion of the 2019 Russell inde...
Initial Purchase by Beijing Dahua Sanxin Technology Development Co., Ltd. Represents First MiOXSYS Commercial Sale in China. ENGLEWOOD, CO / ACCESSWIRE / June 4, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products tha...
ENGLEWOOD, CO / ACCESSWIRE / May 21, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that MiOXSYS®, the company's first-in-class seminal oxidative stress tes...
Aytu BioScience, Inc. (AYTU) Q3 2019 Earnings Conference Call May 14, 2019 9:00 AM ET Company Participants Josh Disbrow - Chairman and Chief Executive Officer David Green - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Inc. ...
SAExploration Holdings (NASDAQ: SAEX ) +18% on Q1 results . More news on: SAExploration Holdings, Inc., StoneCo Ltd., Aytu BioScience, Inc., Stocks on the move, Read more ...
Aytu BioScience (NASDAQ: AYTU ): Q3 GAAP EPS of -$0.50 beats by $0.08 . More news on: Aytu BioScience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / May 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today will provide an overview of its busin...
Live Conference Call and Webcast Scheduled for May 14, 2019, at 9:00 a.m. ET ENGLEWOOD, CO / ACCESSWIRE / May 7, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announ...
Nano cap Aytu BioScience (NASDAQ: AYTU ) announces that licensee SUDA Pharmaceuticals has submitted a marketing application in Australia seeking approval for ZolpiMist (zolpidem tartrate oral spray) for the short-term treatment of insomnia in patients who have difficulty with sleep initi...
Australian TGA Approval Decision Expected in Early 2020 ENGLEWOOD, CO / ACCESSWIRE / April 24, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the ...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...